47 related articles for article (PubMed ID: 25344361)
1. High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II study.
Necchi A; Mariani L; Di Nicola M; Lo Vullo S; Nicolai N; Giannatempo P; Raggi D; Farè E; Magni M; Piva L; Matteucci P; Catanzaro M; Biasoni D; Torelli T; Stagni S; Bengala C; Barone C; Schiavetto I; Siena S; Carlo-Stella C; Pizzocaro G; Salvioni R; Gianni AM
Ann Oncol; 2015 Jan; 26(1):167-172. PubMed ID: 25344361
[TBL] [Abstract][Full Text] [Related]
2. High Dose Chemotherapy With Autologous Stem Cell Transplant for Patients With Advanced Germ Cell Tumors: Real-World Evidence From a Tertiary Cancer Center in Brazil.
Polho GB; Cunha MT; Coelho MHM; Almeida-Silva J; Hidalgo Filho CM; Xavier EM; Crusoe NS; Atanazio MJ; de Vasconcellos VF; Horita VN; Freitas GF; Muniz DQ; Rocha V; Mota JM
Clin Genitourin Cancer; 2024 Jun; 22(3):102083. PubMed ID: 38658209
[TBL] [Abstract][Full Text] [Related]
3. High-dose chemotherapy and stem cell transplantation for advanced testicular cancer.
Voss MH; Feldman DR; Motzer RJ
Expert Rev Anticancer Ther; 2011 Jul; 11(7):1091-103. PubMed ID: 21806332
[TBL] [Abstract][Full Text] [Related]
4. Ototoxicity associated with high-dose carboplatin for patients with previously treated germ cell tumors.
Funt SA; Knezevic A; Wilson K; Bromberg M; Budnick A; O'Connor KL; McHugh DJ; Larsen E; Bajorin DF; Motzer RJ; Tonorezos ES; Patil S; Feldman DR
Cancer; 2023 Dec; 129(24):3952-3961. PubMed ID: 37715631
[TBL] [Abstract][Full Text] [Related]
5. Risk analysis of subsequent therapies after first-line chemotherapy in advanced testicular cancer patients.
Yen TH; Wang SS; Yang CK; Lu K; Chen CS; Cheng CL; Hung SC; Chiu KY; Chen CP; Yang CR; Li JR
J Chin Med Assoc; 2023 Jul; 86(7):646-652. PubMed ID: 37191945
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcome of patients with clinical stage I high-risk nonseminomatous germ-cell tumors 15 years after one adjuvant cycle of bleomycin, etoposide, and cisplatin chemotherapy.
Vidal AD; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
Ann Oncol; 2015 Feb; 26(2):374-7. PubMed ID: 25392157
[TBL] [Abstract][Full Text] [Related]
7. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial.
Perrone F; Nuzzo F; Di Rella F; Gravina A; Iodice G; Labonia V; Landi G; Pacilio C; Rossi E; De Laurentiis M; D'Aiuto M; Botti G; Forestieri V; Lauria R; De Placido S; Tinessa V; Daniele B; Gori S; Colantuoni G; Barni S; Riccardi F; De Maio E; Montanino A; Morabito A; Daniele G; Di Maio M; Piccirillo MC; Signoriello S; Gallo C; de Matteis A
Ann Oncol; 2015 Apr; 26(4):675-682. PubMed ID: 25488686
[TBL] [Abstract][Full Text] [Related]
8. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.
Gnant M; Mlineritsch B; Stoeger H; Luschin-Ebengreuth G; Knauer M; Moik M; Jakesz R; Seifert M; Taucher S; Bjelic-Radisic V; Balic M; Eidtmann H; Eiermann W; Steger G; Kwasny W; Dubsky P; Selim U; Fitzal F; Hochreiner G; Wette V; Sevelda P; Ploner F; Bartsch R; Fesl C; Greil R;
Ann Oncol; 2015 Feb; 26(2):313-20. PubMed ID: 25403582
[TBL] [Abstract][Full Text] [Related]
9. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
[TBL] [Abstract][Full Text] [Related]
10. Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer.
Krop IE; Suter TM; Dang CT; Dirix L; Romieu G; Zamagni C; Citron ML; Campone M; Xu N; Smitt M; Gianni L
J Clin Oncol; 2015 Apr; 33(10):1136-42. PubMed ID: 25713436
[TBL] [Abstract][Full Text] [Related]
11. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids.
Caplin ME; Baudin E; Ferolla P; Filosso P; Garcia-Yuste M; Lim E; Oberg K; Pelosi G; Perren A; Rossi RE; Travis WD;
Ann Oncol; 2015 Aug; 26(8):1604-20. PubMed ID: 25646366
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase III trial comparing weekly docetaxel plus cisplatin versus docetaxel monotherapy every 3 weeks in elderly patients with advanced non-small-cell lung cancer: the intergroup trial JCOG0803/WJOG4307L.
Abe T; Takeda K; Ohe Y; Kudoh S; Ichinose Y; Okamoto H; Yamamoto N; Yoshioka H; Minato K; Sawa T; Iwamoto Y; Saka H; Mizusawa J; Shibata T; Nakamura S; Ando M; Yokoyama A; Nakagawa K; Saijo N; Tamura T
J Clin Oncol; 2015 Feb; 33(6):575-81. PubMed ID: 25584004
[TBL] [Abstract][Full Text] [Related]
13. Salvage treatment for testicular cancer with standard- or high-dose chemotherapy: a systematic review of 59 studies.
Petrelli F; Coinu A; Rosti G; Pedrazzoli P; Barni S
Med Oncol; 2017 Aug; 34(8):133. PubMed ID: 28653284
[TBL] [Abstract][Full Text] [Related]
14. Standard versus high-dose chemotherapy in mediastinal germ cell tumors: a narrative review.
Giunta EF; Ottaviano M; Mosca A; Banna GL; Rescigno P
Mediastinum; 2022; 6():6. PubMed ID: 35340836
[TBL] [Abstract][Full Text] [Related]
15. Squamous Cell Carcinoma Malignantly Transformed From Frequent Recurrence of a Presacral Epidermoid Cyst: Report of a Case.
Wu X; Chen C; Yang M; Yuan X; Chen H; Yin L
Front Oncol; 2020; 10():458. PubMed ID: 32318346
[No Abstract] [Full Text] [Related]
16. First - line, non - cryopreserved autologous stem cell transplant for poor - risk germ - cell tumors: Experience in a developing country.
Leon-Rodriguez E; Rivera-Franco MM; Lacayo-Leñero D; Campos-Castro A; Meneses-Medina MI
Int Braz J Urol; 2019; 45(1):74-82. PubMed ID: 30325602
[TBL] [Abstract][Full Text] [Related]
17. High dose chemotherapy with stem cell support in the treatment of testicular cancer.
Popovic L; Matovina-Brko G; Popovic M; Petrovic D; Cvetanovic A; Vukojevic J; Jovanovic D
World J Stem Cells; 2015 Dec; 7(11):1222-32. PubMed ID: 26730267
[TBL] [Abstract][Full Text] [Related]
18. Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy.
Pol J; Vacchelli E; Aranda F; Castoldi F; Eggermont A; Cremer I; Sautès-Fridman C; Fucikova J; Galon J; Spisek R; Tartour E; Zitvogel L; Kroemer G; Galluzzi L
Oncoimmunology; 2015 Apr; 4(4):e1008866. PubMed ID: 26137404
[TBL] [Abstract][Full Text] [Related]
19. A randomised phase 2 trial of intensive induction chemotherapy (CBOP/BEP) and standard BEP in poor-prognosis germ cell tumours (MRC TE23, CRUK 05/014, ISRCTN 53643604).
Huddart RA; Gabe R; Cafferty FH; Pollock P; White JD; Shamash J; Cullen MH; Stenning SP; ;
Eur Urol; 2015 Mar; 67(3):534-43. PubMed ID: 25001888
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
